| |
Public Act 102-0103 Public Act 0103 102ND GENERAL ASSEMBLY |
Public Act 102-0103 | HB0135 Enrolled | LRB102 02749 BMS 12752 b |
|
| AN ACT concerning regulation.
| Be it enacted by the People of the State of Illinois,
| represented in the General Assembly:
| Section 5. The State Employees Group Insurance Act of 1971 | is amended by changing Section 6.11 as follows:
| (5 ILCS 375/6.11)
| Sec. 6.11. Required health benefits; Illinois Insurance | Code
requirements. The program of health
benefits shall | provide the post-mastectomy care benefits required to be | covered
by a policy of accident and health insurance under | Section 356t of the Illinois
Insurance Code. The program of | health benefits shall provide the coverage
required under | Sections 356g, 356g.5, 356g.5-1, 356m,
356u, 356w, 356x, | 356z.2, 356z.4, 356z.4a, 356z.6, 356z.8, 356z.9, 356z.10, | 356z.11, 356z.12, 356z.13, 356z.14, 356z.15, 356z.17, 356z.22, | 356z.25, 356z.26, 356z.29, 356z.30a, 356z.32, 356z.33, | 356z.36, and 356z.41 , and 356z.43 of the
Illinois Insurance | Code.
The program of health benefits must comply with Sections | 155.22a, 155.37, 355b, 356z.19, 370c, and 370c.1 and Article | XXXIIB of the
Illinois Insurance Code. The Department of | Insurance shall enforce the requirements of this Section with | respect to Sections 370c and 370c.1 of the Illinois Insurance | Code; all other requirements of this Section shall be enforced |
| by the Department of Central Management Services.
| Rulemaking authority to implement Public Act 95-1045, if | any, is conditioned on the rules being adopted in accordance | with all provisions of the Illinois Administrative Procedure | Act and all rules and procedures of the Joint Committee on | Administrative Rules; any purported rule not so adopted, for | whatever reason, is unauthorized. | (Source: P.A. 100-24, eff. 7-18-17; 100-138, eff. 8-18-17; | 100-863, eff. 8-14-18; 100-1024, eff. 1-1-19; 100-1057, eff. | 1-1-19; 100-1102, eff. 1-1-19; 100-1170, eff. 6-1-19; 101-13, | eff. 6-12-19; 101-281, eff. 1-1-20; 101-393, eff. 1-1-20; | 101-452, eff. 1-1-20; 101-461, eff. 1-1-20; 101-625, eff. | 1-1-21 .) | Section 10. The Counties Code is amended by changing | Section 5-1069.3 as follows: | (55 ILCS 5/5-1069.3)
| Sec. 5-1069.3. Required health benefits. If a county, | including a home
rule
county, is a self-insurer for purposes | of providing health insurance coverage
for its employees, the | coverage shall include coverage for the post-mastectomy
care | benefits required to be covered by a policy of accident and | health
insurance under Section 356t and the coverage required | under Sections 356g, 356g.5, 356g.5-1, 356u,
356w, 356x, | 356z.6, 356z.8, 356z.9, 356z.10, 356z.11, 356z.12, 356z.13, |
| 356z.14, 356z.15, 356z.22, 356z.25, 356z.26, 356z.29, | 356z.30a, 356z.32, 356z.33, 356z.36, and 356z.41 , and 356z.43 | of
the Illinois Insurance Code. The coverage shall comply with | Sections 155.22a, 355b, 356z.19, and 370c of
the Illinois | Insurance Code. The Department of Insurance shall enforce the | requirements of this Section. The requirement that health | benefits be covered
as provided in this Section is an
| exclusive power and function of the State and is a denial and | limitation under
Article VII, Section 6, subsection (h) of the | Illinois Constitution. A home
rule county to which this | Section applies must comply with every provision of
this | Section.
| Rulemaking authority to implement Public Act 95-1045, if | any, is conditioned on the rules being adopted in accordance | with all provisions of the Illinois Administrative Procedure | Act and all rules and procedures of the Joint Committee on | Administrative Rules; any purported rule not so adopted, for | whatever reason, is unauthorized. | (Source: P.A. 100-24, eff. 7-18-17; 100-138, eff. 8-18-17; | 100-863, eff. 8-14-18; 100-1024, eff. 1-1-19; 100-1057, eff. | 1-1-19; 100-1102, eff. 1-1-19; 101-81, eff. 7-12-19; 101-281, | eff. 1-1-20; 101-393, eff. 1-1-20; 101-461, eff. 1-1-20; | 101-625, eff. 1-1-21 .) | Section 15. The Illinois Municipal Code is amended by | changing Section 10-4-2.3 as follows: |
| (65 ILCS 5/10-4-2.3)
| Sec. 10-4-2.3. Required health benefits. If a | municipality, including a
home rule municipality, is a | self-insurer for purposes of providing health
insurance | coverage for its employees, the coverage shall include | coverage for
the post-mastectomy care benefits required to be | covered by a policy of
accident and health insurance under | Section 356t and the coverage required
under Sections 356g, | 356g.5, 356g.5-1, 356u, 356w, 356x, 356z.6, 356z.8, 356z.9, | 356z.10, 356z.11, 356z.12, 356z.13, 356z.14, 356z.15, 356z.22, | 356z.25, 356z.26, 356z.29, 356z.30a, 356z.32, 356z.33, | 356z.36, and 356z.41 , and 356z.43 of the Illinois
Insurance
| Code. The coverage shall comply with Sections 155.22a, 355b, | 356z.19, and 370c of
the Illinois Insurance Code. The | Department of Insurance shall enforce the requirements of this | Section. The requirement that health
benefits be covered as | provided in this is an exclusive power and function of
the | State and is a denial and limitation under Article VII, | Section 6,
subsection (h) of the Illinois Constitution. A home | rule municipality to which
this Section applies must comply | with every provision of this Section.
| Rulemaking authority to implement Public Act 95-1045, if | any, is conditioned on the rules being adopted in accordance | with all provisions of the Illinois Administrative Procedure | Act and all rules and procedures of the Joint Committee on |
| Administrative Rules; any purported rule not so adopted, for | whatever reason, is unauthorized. | (Source: P.A. 100-24, eff. 7-18-17; 100-138, eff. 8-18-17; | 100-863, eff. 8-14-18; 100-1024, eff. 1-1-19; 100-1057, eff. | 1-1-19; 100-1102, eff. 1-1-19; 101-81, eff. 7-12-19; 101-281, | eff. 1-1-20; 101-393, eff. 1-1-20; 101-461, eff. 1-1-20; | 101-625, eff. 1-1-21 .) | Section 20. The School Code is amended by changing Section | 10-22.3f as follows: | (105 ILCS 5/10-22.3f)
| Sec. 10-22.3f. Required health benefits. Insurance | protection and
benefits
for employees shall provide the | post-mastectomy care benefits required to be
covered by a | policy of accident and health insurance under Section 356t and | the
coverage required under Sections 356g, 356g.5, 356g.5-1, | 356u, 356w, 356x,
356z.6, 356z.8, 356z.9, 356z.11, 356z.12, | 356z.13, 356z.14, 356z.15, 356z.22, 356z.25, 356z.26, 356z.29, | 356z.30a, 356z.32, 356z.33, 356z.36, and 356z.41 , and 356z.43 | of
the
Illinois Insurance Code.
Insurance policies shall | comply with Section 356z.19 of the Illinois Insurance Code. | The coverage shall comply with Sections 155.22a, 355b, and | 370c of
the Illinois Insurance Code. The Department of | Insurance shall enforce the requirements of this Section.
| Rulemaking authority to implement Public Act 95-1045, if |
| any, is conditioned on the rules being adopted in accordance | with all provisions of the Illinois Administrative Procedure | Act and all rules and procedures of the Joint Committee on | Administrative Rules; any purported rule not so adopted, for | whatever reason, is unauthorized. | (Source: P.A. 100-24, eff. 7-18-17; 100-138, eff. 8-18-17; | 100-863, eff. 8-14-18; 100-1024, eff. 1-1-19; 100-1057, eff. | 1-1-19; 100-1102, eff. 1-1-19; 101-81, eff. 7-12-19; 101-281, | eff. 1-1-20; 101-393, eff. 1-1-20; 101-461, eff. 1-1-20; | 101-625, eff. 1-1-21 .) | Section 25. The Illinois Insurance Code is amended by | adding Section 356z.43 as follows: | (215 ILCS 5/356z.43 new) | Sec. 356z.43. Coverage for patient care services provided | by a pharmacist. A group or individual policy of accident and | health insurance or a managed care plan that is amended, | delivered, issued, or renewed on or after January 1, 2023 | shall provide coverage for health care or patient care | services provided by a pharmacist if: | (1) the pharmacist meets the requirements and scope of | practice as set forth in Section 43 of the Pharmacy | Practice Act; | (2) the health plan provides coverage for the same | service provided by a licensed physician, an advanced |
| practice registered nurse, or a physician assistant; | (3) the pharmacist is included in the health benefit | plan's network of participating providers; and | (4) a reimbursement has been successfully negotiated | in good faith between the pharmacist and the health plan. | Section 30. The Pharmacy Practice Act is amended by | changing Section 3 and by adding Section 43 as follows:
| (225 ILCS 85/3)
| (Section scheduled to be repealed on January 1, 2023)
| Sec. 3. Definitions. For the purpose of this Act, except | where otherwise
limited therein:
| (a) "Pharmacy" or "drugstore" means and includes every | store, shop,
pharmacy department, or other place where | pharmacist
care is
provided
by a pharmacist (1) where drugs, | medicines, or poisons are
dispensed, sold or
offered for sale | at retail, or displayed for sale at retail; or
(2)
where
| prescriptions of physicians, dentists, advanced practice | registered nurses, physician assistants, veterinarians, | podiatric physicians, or
optometrists, within the limits of | their
licenses, are
compounded, filled, or dispensed; or (3) | which has upon it or
displayed within
it, or affixed to or used | in connection with it, a sign bearing the word or
words | "Pharmacist", "Druggist", "Pharmacy", "Pharmaceutical
Care", | "Apothecary", "Drugstore",
"Medicine Store", "Prescriptions", |
| "Drugs", "Dispensary", "Medicines", or any word
or words of | similar or like import, either in the English language
or any | other language; or (4) where the characteristic prescription
| sign (Rx) or similar design is exhibited; or (5) any store, or
| shop,
or other place with respect to which any of the above | words, objects,
signs or designs are used in any | advertisement.
| (b) "Drugs" means and includes (1) articles recognized
in | the official United States Pharmacopoeia/National Formulary | (USP/NF),
or any supplement thereto and being intended for and | having for their
main use the diagnosis, cure, mitigation, | treatment or prevention of
disease in man or other animals, as | approved by the United States Food and
Drug Administration, | but does not include devices or their components, parts,
or | accessories; and (2) all other articles intended
for and | having for their main use the diagnosis, cure, mitigation,
| treatment or prevention of disease in man or other animals, as | approved
by the United States Food and Drug Administration, | but does not include
devices or their components, parts, or | accessories; and (3) articles
(other than food) having for | their main use and intended
to affect the structure or any | function of the body of man or other
animals; and (4) articles | having for their main use and intended
for use as a component | or any articles specified in clause (1), (2)
or (3); but does | not include devices or their components, parts or
accessories.
| (c) "Medicines" means and includes all drugs intended for
|
| human or veterinary use approved by the United States Food and | Drug
Administration.
| (d) "Practice of pharmacy" means: | (1) the interpretation and the provision of assistance | in the monitoring, evaluation, and implementation of | prescription drug orders; | (2) the dispensing of prescription drug orders; | (3) participation in drug and device selection; | (4) drug administration limited to the administration | of oral, topical, injectable, and inhalation as follows: | (A) in the context of patient education on the | proper use or delivery of medications; | (B) vaccination of patients 14 years of age and | older pursuant to a valid prescription or standing | order, by a physician licensed to practice medicine in | all its branches, upon completion of appropriate | training, including how to address contraindications | and adverse reactions set forth by rule, with | notification to the patient's physician and | appropriate record retention, or pursuant to hospital | pharmacy and therapeutics committee policies and | procedures; | (B-5) following the initial administration of | long-acting or extended-release extended release form | opioid antagonists by a physician licensed to practice | medicine in all its branches, administration of |
| injections of long-acting or extended-release form | opioid antagonists for the treatment of substance use | disorder, pursuant to a valid prescription by a | physician licensed to practice medicine in all its | branches, upon completion of appropriate training, | including how to address contraindications and adverse | reactions, including, but not limited to, respiratory | depression and the performance of cardiopulmonary | resuscitation, set forth by rule, with notification to | the patient's physician and appropriate record | retention, or pursuant to hospital pharmacy and | therapeutics committee policies and procedures; | (C) administration of injections of | alpha-hydroxyprogesterone caproate, pursuant to a | valid prescription, by a physician licensed to | practice medicine in all its branches, upon completion | of appropriate training, including how to address | contraindications and adverse reactions set forth by | rule, with notification to the patient's physician and | appropriate record retention, or pursuant to hospital | pharmacy and therapeutics committee policies and | procedures; and | (D) administration of injections of long-term | antipsychotic medications pursuant to a valid | prescription by a physician licensed to practice | medicine in all its branches, upon completion of |
| appropriate training conducted by an Accreditation | Council of Pharmaceutical Education accredited | provider, including how to address contraindications | and adverse reactions set forth by rule, with | notification to the patient's physician and | appropriate record retention, or pursuant to hospital | pharmacy and therapeutics committee policies and | procedures. | (5) vaccination of patients ages 10 through 13 limited | to the Influenza (inactivated influenza vaccine and live | attenuated influenza intranasal vaccine) and Tdap (defined | as tetanus, diphtheria, acellular pertussis) vaccines, | pursuant to a valid prescription or standing order, by a | physician licensed to practice medicine in all its | branches, upon completion of appropriate training, | including how to address contraindications and adverse | reactions set forth by rule, with notification to the | patient's physician and appropriate record retention, or | pursuant to hospital pharmacy and therapeutics committee | policies and procedures; | (6) drug regimen review; | (7) drug or drug-related research; | (8) the provision of patient counseling; | (9) the practice of telepharmacy; | (10) the provision of those acts or services necessary | to provide pharmacist care; |
| (11) medication therapy management; and | (12) the responsibility for compounding and labeling | of drugs and devices (except labeling by a manufacturer, | repackager, or distributor of non-prescription drugs and | commercially packaged legend drugs and devices), proper | and safe storage of drugs and devices, and maintenance of | required records ; and . | (13) the assessment and consultation of patients and | dispensing of hormonal contraceptives. | A pharmacist who performs any of the acts defined as the | practice of pharmacy in this State must be actively licensed | as a pharmacist under this Act.
| (e) "Prescription" means and includes any written, oral, | facsimile, or
electronically transmitted order for drugs
or | medical devices, issued by a physician licensed to practice | medicine in
all its branches, dentist, veterinarian, podiatric | physician, or
optometrist, within the
limits of his or her | license, by a physician assistant in accordance with
| subsection (f) of Section 4, or by an advanced practice | registered nurse in
accordance with subsection (g) of Section | 4, containing the
following: (1) name
of the patient; (2) date | when prescription was issued; (3) name
and strength of drug or | description of the medical device prescribed;
and (4) | quantity; (5) directions for use; (6) prescriber's name,
| address,
and signature; and (7) DEA registration number where | required, for controlled
substances.
The prescription may, but |
| is not required to, list the illness, disease, or condition | for which the drug or device is being prescribed. DEA | registration numbers shall not be required on inpatient drug | orders. A prescription for medication other than controlled | substances shall be valid for up to 15 months from the date | issued for the purpose of refills, unless the prescription | states otherwise.
| (f) "Person" means and includes a natural person, | partnership,
association, corporation, government entity, or | any other legal
entity.
| (g) "Department" means the Department of Financial and
| Professional Regulation.
| (h) "Board of Pharmacy" or "Board" means the State Board
| of Pharmacy of the Department of Financial and Professional | Regulation.
| (i) "Secretary"
means the Secretary
of Financial and | Professional Regulation.
| (j) "Drug product selection" means the interchange for a
| prescribed pharmaceutical product in accordance with Section | 25 of
this Act and Section 3.14 of the Illinois Food, Drug and | Cosmetic Act.
| (k) "Inpatient drug order" means an order issued by an | authorized
prescriber for a resident or patient of a facility | licensed under the
Nursing Home Care Act, the ID/DD Community | Care Act, the MC/DD Act, the Specialized Mental Health | Rehabilitation Act of 2013, the Hospital Licensing Act, or the |
| University of Illinois Hospital Act, or a facility which is | operated by the Department of Human
Services (as successor to | the Department of Mental Health
and Developmental | Disabilities) or the Department of Corrections.
| (k-5) "Pharmacist" means an individual health care | professional and
provider currently licensed by this State to | engage in the practice of
pharmacy.
| (l) "Pharmacist in charge" means the licensed pharmacist | whose name appears
on a pharmacy license and who is | responsible for all aspects of the
operation related to the | practice of pharmacy.
| (m) "Dispense" or "dispensing" means the interpretation, | evaluation, and implementation of a prescription drug order, | including the preparation and delivery of a drug or device to a | patient or patient's agent in a suitable container | appropriately labeled for subsequent administration to or use | by a patient in accordance with applicable State and federal | laws and regulations.
"Dispense" or "dispensing" does not mean | the physical delivery to a patient or a
patient's | representative in a home or institution by a designee of a | pharmacist
or by common carrier. "Dispense" or "dispensing" | also does not mean the physical delivery
of a drug or medical | device to a patient or patient's representative by a
| pharmacist's designee within a pharmacy or drugstore while the | pharmacist is
on duty and the pharmacy is open.
| (n) "Nonresident pharmacy"
means a pharmacy that is |
| located in a state, commonwealth, or territory
of the United | States, other than Illinois, that delivers, dispenses, or
| distributes, through the United States Postal Service, | commercially acceptable parcel delivery service, or other | common
carrier, to Illinois residents, any substance which | requires a prescription.
| (o) "Compounding" means the preparation and mixing of | components, excluding flavorings, (1) as the result of a | prescriber's prescription drug order or initiative based on | the prescriber-patient-pharmacist relationship in the course | of professional practice or (2) for the purpose of, or | incident to, research, teaching, or chemical analysis and not | for sale or dispensing. "Compounding" includes the preparation | of drugs or devices in anticipation of receiving prescription | drug orders based on routine, regularly observed dispensing | patterns. Commercially available products may be compounded | for dispensing to individual patients only if all of the | following conditions are met: (i) the commercial product is | not reasonably available from normal distribution channels in | a timely manner to meet the patient's needs and (ii) the | prescribing practitioner has requested that the drug be | compounded.
| (p) (Blank).
| (q) (Blank).
| (r) "Patient counseling" means the communication between a | pharmacist or a student pharmacist under the supervision of a |
| pharmacist and a patient or the patient's representative about | the patient's medication or device for the purpose of | optimizing proper use of prescription medications or devices. | "Patient counseling" may include without limitation (1) | obtaining a medication history; (2) acquiring a patient's | allergies and health conditions; (3) facilitation of the | patient's understanding of the intended use of the medication; | (4) proper directions for use; (5) significant potential | adverse events; (6) potential food-drug interactions; and (7) | the need to be compliant with the medication therapy. A | pharmacy technician may only participate in the following | aspects of patient counseling under the supervision of a | pharmacist: (1) obtaining medication history; (2) providing | the offer for counseling by a pharmacist or student | pharmacist; and (3) acquiring a patient's allergies and health | conditions.
| (s) "Patient profiles" or "patient drug therapy record" | means the
obtaining, recording, and maintenance of patient | prescription
information, including prescriptions for | controlled substances, and
personal information.
| (t) (Blank).
| (u) "Medical device" or "device" means an instrument, | apparatus, implement, machine,
contrivance, implant, in vitro | reagent, or other similar or related article,
including any | component part or accessory, required under federal law to
| bear the label "Caution: Federal law requires dispensing by or |
| on the order
of a physician". A seller of goods and services | who, only for the purpose of
retail sales, compounds, sells, | rents, or leases medical devices shall not,
by reasons | thereof, be required to be a licensed pharmacy.
| (v) "Unique identifier" means an electronic signature, | handwritten
signature or initials, thumb print, or other | acceptable biometric
or electronic identification process as | approved by the Department.
| (w) "Current usual and customary retail price" means the | price that a pharmacy charges to a non-third-party payor.
| (x) "Automated pharmacy system" means a mechanical system | located within the confines of the pharmacy or remote location | that performs operations or activities, other than compounding | or administration, relative to storage, packaging, dispensing, | or distribution of medication, and which collects, controls, | and maintains all transaction information. | (y) "Drug regimen review" means and includes the | evaluation of prescription drug orders and patient records for | (1)
known allergies; (2) drug or potential therapy | contraindications;
(3) reasonable dose, duration of use, and | route of administration, taking into consideration factors | such as age, gender, and contraindications; (4) reasonable | directions for use; (5) potential or actual adverse drug | reactions; (6) drug-drug interactions; (7) drug-food | interactions; (8) drug-disease contraindications; (9) | therapeutic duplication; (10) patient laboratory values when |
| authorized and available; (11) proper utilization (including | over or under utilization) and optimum therapeutic outcomes; | and (12) abuse and misuse.
| (z) "Electronically transmitted prescription" means a | prescription that is created, recorded, or stored by | electronic means; issued and validated with an electronic | signature; and transmitted by electronic means directly from | the prescriber to a pharmacy. An electronic prescription is | not an image of a physical prescription that is transferred by | electronic means from computer to computer, facsimile to | facsimile, or facsimile to computer.
| (aa) "Medication therapy management services" means a | distinct service or group of services offered by licensed | pharmacists, physicians licensed to practice medicine in all | its branches, advanced practice registered nurses authorized | in a written agreement with a physician licensed to practice | medicine in all its branches, or physician assistants | authorized in guidelines by a supervising physician that | optimize therapeutic outcomes for individual patients through | improved medication use. In a retail or other non-hospital | pharmacy, medication therapy management services shall consist | of the evaluation of prescription drug orders and patient | medication records to resolve conflicts with the following: | (1) known allergies; | (2) drug or potential therapy contraindications; | (3) reasonable dose, duration of use, and route of |
| administration, taking into consideration factors such as | age, gender, and contraindications; | (4) reasonable directions for use; | (5) potential or actual adverse drug reactions; | (6) drug-drug interactions; | (7) drug-food interactions; | (8) drug-disease contraindications; | (9) identification of therapeutic duplication; | (10) patient laboratory values when authorized and | available; | (11) proper utilization (including over or under | utilization) and optimum therapeutic outcomes; and | (12) drug abuse and misuse. | "Medication therapy management services" includes the | following: | (1) documenting the services delivered and | communicating the information provided to patients' | prescribers within an appropriate time frame, not to | exceed 48 hours; | (2) providing patient counseling designed to enhance a | patient's understanding and the appropriate use of his or | her medications; and | (3) providing information, support services, and | resources designed to enhance a patient's adherence with | his or her prescribed therapeutic regimens. | "Medication therapy management services" may also include |
| patient care functions authorized by a physician licensed to | practice medicine in all its branches for his or her | identified patient or groups of patients under specified | conditions or limitations in a standing order from the | physician. | "Medication therapy management services" in a licensed | hospital may also include the following: | (1) reviewing assessments of the patient's health | status; and | (2) following protocols of a hospital pharmacy and | therapeutics committee with respect to the fulfillment of | medication orders.
| (bb) "Pharmacist care" means the provision by a pharmacist | of medication therapy management services, with or without the | dispensing of drugs or devices, intended to achieve outcomes | that improve patient health, quality of life, and comfort and | enhance patient safety.
| (cc) "Protected health information" means individually | identifiable health information that, except as otherwise | provided, is:
| (1) transmitted by electronic media; | (2) maintained in any medium set forth in the | definition of "electronic media" in the federal Health | Insurance Portability and Accountability Act; or | (3) transmitted or maintained in any other form or | medium. |
| "Protected health information" does not include | individually identifiable health information found in: | (1) education records covered by the federal Family | Educational Right and Privacy Act; or | (2) employment records held by a licensee in its role | as an employer. | (dd) "Standing order" means a specific order for a patient | or group of patients issued by a physician licensed to | practice medicine in all its branches in Illinois. | (ee) "Address of record" means the designated address | recorded by the Department in the applicant's application file | or licensee's license file maintained by the Department's | licensure maintenance unit. | (ff) "Home pharmacy" means the location of a pharmacy's | primary operations.
| (gg) "Email address of record" means the designated email | address recorded by the Department in the applicant's | application file or the licensee's license file, as maintained | by the Department's licensure maintenance unit. | (Source: P.A. 100-208, eff. 1-1-18; 100-497, eff. 9-8-17; | 100-513, eff. 1-1-18; 100-804, eff. 1-1-19; 100-863, eff. | 8-14-18; 101-349, eff. 1-1-20; revised 8-21-20.) | (225 ILCS 85/43 new) | Sec. 43. Dispensation of hormonal contraceptives. | (a) The dispensing of hormonal contraceptives to a patient |
| shall be pursuant to a valid prescription or standing order by | a physician licensed to practice medicine in all its branches | or the medical director of a local health department, pursuant | to the following: | (1) a pharmacist may dispense no more than a 12-month | supply of hormonal contraceptives to a patient; | (2) a pharmacist must complete an educational training | program accredited by the Accreditation Council for | Pharmacy Education and approved by the Department that is | related to the patient self-screening risk assessment, | patient assessment contraceptive counseling and education, | and dispensation of hormonal contraceptives; | (3) a pharmacist shall have the patient complete the | self-screening risk assessment tool; the self-screening | risk assessment tool is to be based on the most current | version of the United States Medical Eligibility Criteria | for Contraceptive Use published by the federal Centers for | Disease Control and Prevention; | (4) based upon the results of the self-screening risk | assessment and the patient assessment, the pharmacist | shall use his or her professional and clinical judgment as | to when a patient should be referred to the patient's | physician or another health care provider; | (5) a pharmacist shall provide, during the patient | assessment and consultation, counseling and education | about all methods of contraception, including methods not |
| covered under the standing order, and their proper use and | effectiveness; | (6) the patient consultation shall take place in a | private manner; and | (7) a pharmacist and pharmacy must maintain | appropriate records. | (b) The Department may adopt rules to implement this | Section. | (c) Nothing in this Section shall be interpreted to | require a pharmacist to dispense hormonal contraception under | a standing order issued by a physician licensed to practice | medicine in all its branches or
the medical director of a local | health department. | Section 35. The Illinois Public Aid Code is amended by | adding Section 5-5.12d as follows: | (305 ILCS 5/5-5.12d new) | Sec. 5-5.12d. Coverage for patient care services for | hormonal contraceptives provided by a pharmacist. | (a) Subject to approval by the federal Centers for | Medicare and Medicaid Services, the medical assistance | program, including both the fee-for-service and managed care | medical assistance programs established under this Article, | shall cover patient care services provided by a pharmacist for | hormonal contraceptives assessment and consultation. |
| (b) The Department shall establish a fee schedule for | patient care services provided by a pharmacist for hormonal | contraceptives assessment and consultation. | (c) The rate of reimbursement for patient care services | provided by a pharmacist for hormonal contraceptives | assessment and consultation shall be at 85% of the fee | schedule for physician services by the medical assistance | program. | (d) A pharmacist must be enrolled in the medical | assistance program as an ordering and referring provider prior | to providing hormonal contraceptives assessment and | consultation that is submitted by a pharmacy or pharmacist | provider for reimbursement pursuant to this Section. | (e) The Department shall apply for any necessary federal | waivers or approvals to implement this Section by January 1, | 2022. | (f) This Section does not restrict or prohibit any | services currently provided by pharmacists as authorized by | law, including, but not limited to, pharmacist services | provided under this Code or authorized under the Illinois | Title XIX State Plan. | (g) The Department shall submit to the Joint Committee on | Administrative Rules administrative rules for this Section as | soon as practicable but no later than 6 months after federal | approval is received.
| Section 99. Effective date. This Act takes effect on |
| January 1, 2022, except that Section 25 takes effect on | January 1, 2023. |
Effective Date: 1/1/2022
|
|
|